Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Neurology and Neuroscience Reports
Erschienen in: Current Neurology and Neuroscience Reports 8/2021

01.08.2021 | Headache (R.B. Halker Singh and J. VanderPluym, Section Editors)

Approach to Pediatric Intractable Migraine

verfasst von: Mohammed Alqahtani, Rebecca Barmherzig, Ana Marissa Lagman-Bartolome

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Intractable migraine in children and adolescents is a significant cause of disability and decreased quality of life (QoL) in this population. Challenges include lack of unifying definition for intractable migraine, and limited data on best-practice management in this age group, with most current treatment pathways extrapolated from adult studies or expert consensus.

Recent Findings

A comprehensive approach in the evaluation and management of intractable migraine in this age group encompasses excluding secondary causes of headache; making an accurate diagnosis; identifying and appropriately managing modifiable risk factors; and initiating appropriate pharmacologic therapy to reduce disability, improve health-related quality of life, reduce risk of progression, and develop adaptive pain coping strategies. Several strategies for management of pediatric intractable migraine including use of acute medications, bridge therapy in outpatient setting, emerging therapies for preventive therapy, and a stepwise combination therapy for management of pediatric intractable migraine in emergency and inpatient setting are presented based on available clinical data, safety/tolerability, availability, cost-effectiveness, and expert consensus.

Summary

This descriptive review of the available literature focuses on approach to therapy for acute intractable migraine in a pediatric population including outpatient, emergency department (ED), and inpatient management.
Literatur
1.
Powers SW, Patton SR, Hommel KA, Hershey AD. Quality of life in childhood migraines: clinical impact and comparison to other chronic illnesses. Pediatrics. 2003;112(1 Pt1):1–5.CrossRef
2.
Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia. 2010;30:1065–72.PubMedCrossRef
3.
Lipton RB, Manack A, Ricci JA, Chee E, Turkel CC, Winner P. Prevalence and burden of chronic migraine in adolescents: results of the chronic daily headache in adolescents study (C-dAS). Headache. 2011;51(5):693–706.PubMedCrossRef
4.
Goadsby PJ, Schoenen J, Ferrari MD, Silberstein SD, Dodick D. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia. 2006;26:1168–70.PubMedCrossRef
5.
6.
Kabbouche MA, Linder SL. Management of migraine in children and adolescents in the emergency department and inpatient setting. Curr Pain Headache Rep. 2005;9(5):363–7.PubMedCrossRef
7.
Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174–82.PubMedCrossRef
8.
9.
Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain. 2001;89(2–3):107–10.PubMedCrossRef
10.
Goadsby PJ, Holland PR, Marins-Liveira M, et al. Pathophysiology of migraine. A disorder of sensory processing. Physiol Rev. 2017;90:553–622.CrossRef
11.
Ashina M, Hansen JM, Do TP, MeloCarrillo A, Burstein R, Moskowitz MA. Migraine and the trigeminovascular system—40 years and counting. Lancet Neurol. 2019;18:795–804.PubMedPubMedCentralCrossRef
12.
Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10(9):895–926.PubMedPubMedCentralCrossRef
13.
Dodick DW. Reflections and speculations on refractory migraine: why do some patients fail to improve with currently available therapies? Headache. 2008;48(6):828–37.PubMedCrossRef
14.
Schulman E . Refractory migraine-a review. Refractory Migraine - A Review. Headache. 2013;53(4):599–613.CrossRef
15.••
Orr, S.L., Kabbouche, M.A., O’Brien, H.L. et al. Paediatric migraine: evidence-based management and future directions. Nat Rev Neurol. 2018;14, 515–527. This is a comprehensive review of evidence-based management of pediatric migraine focusing on goals of therapy as well as multidisciplinary approach treatment strategies and pharmacologic treatment.
16.
Buse DC, Greisman JD, Baigi K, Lipton RB. Migraine progression: a systematic review. Headache. 2019;59:306–38.PubMedCrossRef
17.••
Werner K, Qaiser S, Kabbouche M, Murphy B, Maconochie I, Hershey AD. Intravenous migraine treatment in children and adolescents. Curr Pain Headache Rep. 2020 8;24(8):45. This is a review of the different intravenous migraine treatment in children and adolescents used in the emergency department or inpatient setting.
18.
Loder E, Weizenbaum E, Frishberg B, Silberstein S. American Headache Society Choosing Wisely Task Force. Choosing wisely in headache medicine: the American Headache Society’s list of five things physicians and patients should question. Headache. 2013;53(10):1651–9.PubMedCrossRef
19.
Minen MT, Tanev K, Friedman BW. Evaluation and treatment of migraine in the emergency department: a review. Headache: The Journal of Head and Face Pain. 2014;54:1131–45.CrossRef
20.
Richer LP, Laycock K, Millar K, Fitzpatrick E, Khangura S, Bhatt M, et al. Treatment of children with migraine in emergency departments: national practice variation study. Pediatrics. 2010;126:e150–5.PubMedCrossRef
21.••
Oskoui M, Pringsheim T, Holler-Managan Y, Potrebic S, Billinghurst L, Gloss D, Hershey AD, Licking N, Sowell M, Victorio MC, Gersz EM, Leininger E, Zanitsch H, Yonker M, Mack K. Practice guideline update summary: acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Headache. 2019;59(8):1158-1173. This is a comprehensive guideline providing an updated evidence-based recommendation on pharmacologic management for acute treatment of in children and adolescents.
22.••
Szperka CL, Ailani J, Barmherzig R, et al, Migraine care in the era of COVID-19: clinical pearls and plea to insurers.Headache.2020;60:833-842 This is a review article on using different treatment evidence-based and “real world” strategies for migraine treatment including acute, bridge, and preventive therapies which may be tried for which do not require in-person visits to clinic or the emergency department in the era of COVID-19 pandemic.
23.
Chi PW, Hsieh KY, Chen KY, Hsu CW, Bai CH, Chen C, et al. Intranasal lidocaine for acute migraine: a meta-analysis of randomized controlled trials. PLoS One. 2019;14(10):e0224285.PubMedPubMedCentralCrossRef
24.
Cossack M, Nabrinsky E, Turner H, Abraham A, Gratton S. Timolol eyedrops in the treatment of acute migraine attacks: a randomized crossover study. JAMA Neurol. 2018;75(8):1024–5.PubMedPubMedCentralCrossRef
25.
Kurian A, Reghunadhan I, Thilak P, Soman I, Nair U. Short-term efficacy and safety of topical β-blockers (timolol maleate ophthalmic solution, 0.5%) in acute migraine: a randomized crossover trial. JAMA Ophthalmol. 2020;138(11):1160–6.PubMedCrossRef
26.
Burton LJ, Quinn B, Pratt-Cheney JL, Pourani M. Headache etiology in a pediatric emergency department. Pediatr Emerg Care. 1997;13(1):1–4.PubMedCrossRef
27.
Massano D, Julliand S, Kanagarajah L, Gautier M, Vizeneux A, Elmaleh M, et al. Headache with focal neurologic signs in children at the emergency department. J Pediatr. 2014;165(2):376–82.PubMedCrossRef
28.
Insinga RP, Ng-Mark DS. Hanson ME Costs associated with out-patient, emergency room and inpatient care for migraine in the USA. Cephalgia. 2011;31(15):1570–5.CrossRef
29.
Richer L, Craig W, Rowe B. Randomized controlled trial of treatment expectation and intravenous fluid in pediatric migraine. Headache: The Journal of Head and Face Pain. 2014;54:1496–505.CrossRef
30.
Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. Anesth Analg. 2013;116(5):1063–75.PubMedCrossRef
31.
Brousseau DC, Duffy SJ, Anderson AC, Linakis JG. Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. Ann Emerg Med. 2004;43(2):256–62.PubMedCrossRef
32.
Sheridan DC, Laurie A, Pacheco S, Fu R, Hansen ML, Ma OJ, et al. Relative effectiveness of dopamine antagonists for pediatric migraine in the emergency department. Pediatr Emerg Care. 2018;34(3):165–8.PubMedCrossRef
33.
Bachur RG, Monuteaux MC, Neuman MI. A comparison of acute treatment regimens for migraine in the emergency department. Pediatrics. 2015;135:232–8.PubMedCrossRef
34.
Bianchi A, Salomone S, Caraci F, Pizza V, Bernardini R, D’Amato CC. Role of magnesium, coenzyme Q10, riboflavin, and vitamin B12 in migraine prophylaxis. Vitam Horm. 2004;69:297–312.PubMedCrossRef
35.
Mody I, Lambert JDC, Heinemann V. Low extracellular magnesium induces epileptiform activity and spreading depression in rat hippocampal slices. J Neurophysiol. 1987;57:869–88.PubMedCrossRef
36.
Lodi R, Montagna P, Soriani S, Iotti S, Arnaldi C, Cortelli P, et al. Deficit of brain and skeletal muscle bioenergetics and low brain magnesium in juvenile migraine: an in vivo 31P magnetic resonance spectroscopy interictal study. Pediatr Res. 1997;42:866–71.PubMedCrossRef
37.
Shahrami A, Assarzadegan F, Hatamabadi HR, Asgarzadeh M, Sarehbandi B, Asgarzadeh S. Comparison of therapeutic effects of magnesium sulfate vs. dexamethasone/metoclopramide on alleviating acute migraine headache. J Emerg Med. 2015;48(1):69–76.PubMedCrossRef
38.
Mauskop A, Altura BT, Cracco RQ, Altura BM. Intravenous magnesium sulfate rapidly alleviates headaches of various types. Headache. 1996;36(3):154–60.PubMedCrossRef
39.
Orr SL, Aube A, Becker WJ, et al. Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings. Cephalalgia. 2015;35:271–84.PubMedCrossRef
40.
Choi H, Parmar N. The use of intravenous magnesium sulphate for acute migraine: meta-analysis of randomized controlled trials. Eur J Emerg Med. 2014;21:2–9.PubMed
41.
Martinez Cardenas V, Rodriguez M, Burke M, et al. Efficacy and safety of intravenous magnesium sulfate treatment in pediatric patients with headaches. Headache. 2012; 52: 896.
42.
Gertsch E, Loharuka S, Wolter-Warmerdam K, Tong S, Kempe A, Kedia S. Intravenous magnesium as acute treatment for headaches: a pediatric case series. J Emerg Med. 2014;46(2):308–12.PubMedCrossRef
43.
Yokoyama K, Takahashi N, Yada Y. Prolonged maternal magnesium administration and bone metabolism in neonates. Early Hum Dev. 2010;86:187–91.PubMedCrossRef
44.
Palermo A, Fierro B, Giglia G, Cosentino G, Puma AR, Brighina F. Neurosci Lett. Modulation of visual cortex excitability in migraine with aura: effects of valproate therapy. 2009;467(1):26–9.
45.
Shahien R, Saleh SA, Bowirrat A. Intravenous sodium valproate aborts migraine headaches rapidly. Acta Neurol Scand. 2011;123(4):257–65.PubMedCrossRef
46.
Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache. 2001;41(10):976–80.PubMedCrossRef
47.
Giffin NJ, Ruggiero L, Lipton RB, Silberstein SD, Tvedskov JF, Olesen J, et al. Premonitory symptoms in migraine: an electronic diary study. Neurology. 2003;60(6):935–40.PubMedCrossRef
48.
Loga P, Lewis D. Compazine in migraine. Emergency Medicine Journal (BMJ). 2007;24(4):297–8.CrossRef
49.
Bell R, Montoya D, Shuaib A, Lee MA. A comparative trial of three agents in the treatment of acute migraine headache. Ann Emerg Med. 1990;19(10):1079–82.PubMedCrossRef
50.
Leniger T, Pageler L, Stude P, Diener HC, Limmroth V. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache. 2005;45(1):42–6.PubMedCrossRef
51.
Tanen DA, Miller S, French T, Riffenburgh RH. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med. 2003;41(6):847–53.PubMedCrossRef
52.
Zafar MS, Stewart AM, Toupin DN, Cook AM, Baumann RJ. Continuous intravenous valproate as abortive therapy for pediatric status migrainosus. Neurologist. 2018;23(2):43–6.PubMedCrossRef
53.
Sheridan D, Sun B, O’Brien P, Hansen M. Intravenous sodium valproate for acute pediatric headache. J Emerg Med. 2015;49(4):541–5.PubMedCrossRef
54.
Reiter PD, Nickisch J, Merritt G. Efficacy and tolerability of intravenous valproic acid in acute adolescent migraine. Headache. 2005;45(7):899–903.PubMedCrossRef
55.
Kanis JM, Timm NL. Chlorpromazine for the treatment of migraine in a pediatric emergency department. Headache. 2014;54(2):335–42.PubMedCrossRef
56.
Sheridan DC, Meckler GD. Inpatient pediatric migraine treatment: does choice of abortive therapy affect length of stay? J Pediatr. 2016;179:211–5.PubMedCrossRef
57.
Mathew NT, Kailasam J, Meadors L, Chernschev O, Gentry P. Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report. Headache. 2000;40:720–7.PubMedCrossRef
58.
Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand. 2006;114(1):1–7.PubMedCrossRef
59.
Edvinsson L, Haanes KA, Warfvinge K. Does inflammation have a role in migraine? Nat Rev Neurol. 2019;15(8):483–90.PubMedCrossRef
60.
Orr SL, Friedman BW, Christie S, Minen MT, Bamford C, Kelley NE, et al. Management of adults with acute migraine in the emergency department: the American Headache Society evidence assessment of parenteral pharmacotherapies. Headache. 2016;56(6):911–40.PubMedCrossRef
61.
Cobb-Pitstick KM, Hershey AD, O’Brien HL, Kabbouche MA, LeCates S, White S, et al. Factors influencing migraine recurrence after infusion and inpatient migraine treatment in children and adolescents. Headache. 2015;55(10):1397–403.PubMedCrossRef
62.
63.
Kabbouche MA, Powers SW, Segers A, LeCates S, Manning P, Biederman S, et al. Treatment of status migraine with dihydroergotamine in children and adolescents. Headache. 2009;49:106–9.PubMedCrossRef
64.
65.
Carleton SC, Shesser RF, Pietrzak MP, Chudnofsky CR, Starkman S, Morris D, et al. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache. Ann Emerg Med. 1998;32:129–1389.PubMedCrossRef
66.
Raskin NH. Repetitive intravenous DHE therapy for intractable migraine. Neurology. 1986;36:995–7.PubMedCrossRef
67.
Callaham M, Raskin N. A controlled study of DHE in the treatment of acute migraine headache. Headache. 1986;26:168–71.PubMedCrossRef
68.
Bilhimer MH, Groth ME, Holmes AK. Ketamine for migraine in the emergency department. Adv Emerg Nurs J. 2020;42(2):96–102.PubMedCrossRef
69.
Sheridan DC, Spiro DM, Nguyen T, Koch TK, Meckler GD. Low-dose propofol for the abortive treatment of pediatric migraine in the emergency department. Pediatr Emerg Care. 2012;28(12):1293–6.PubMedCrossRef
70.
Ayulo MA Jr, Phillips KE, Tripathi S. Safety and efficacy of IV lidocaine in the treatment of children and adolescents with status migraine. Pediatr Crit Care Med. 2018;19(8):755–9.PubMedCrossRef
71.
72.
Szperka CL, Gelfand AA, Hershey AD. Patterns of use of peripheral nerve blocks and trigger point injections for pediatric headache: results of a survey of the American Headache Society Pediatric and Adolescent Section. Headache. 2016;56(10):1597–607.PubMedPubMedCentralCrossRef
73.
Puledda F, Goadsby PJ, Prabhakar P. Treatment of disabling headache with greater occipital nerve injections in a large population of childhood and adolescent patients: a service evaluation. J Headache Pain. 2018;19(1):5.PubMedPubMedCentralCrossRef
74.
Gelfand AA, Reider AC, Goadsby PJ. Outcomes of greater occipital nerve injections in pediatric patients with chronic primary headache disorders. Pediatr Neurol. 2014;50(2):135–9.PubMedCrossRef
75.
Lambrinakos-Raymond K, Dubrovsky A. Nerve blocks in paediatric and adolescent headache disorders. Current Opinion in Pediatrics. 2018;30(6):780-785.
76.
Khan S, Schoenen J, Ashina M. Sphenopalatine ganglion neuromodulation in migraine: what is the rationale? Cephalagia. 2014;34(5):382–91.CrossRef
77.
Cady R, Saper J, Dexter K, Manley HR. A double-blind, placebo-controlled study of repetitive transnasal sphenopalatine ganglion blockade with Tx360® as acute treatment for chronic migraine. Headache. 2015;55(1):101–16.PubMedCrossRef
78.
Huguet A, Tougas ME, Hayden J, McGrath PJ, Chambers CT, Stinson JN, Wozney L. Systematic review of childhood and adolescent risk and prognostic factors for recurrent headaches. J Pain. 2016;17(8):855-873.e8.
79.
Robberstad L, Dyb G, Hagen K, Stovner LJ, Holmen TL, Zwart JA. An unfavorable lifestyle and 34 recurrent headaches among adolescents: the HUNT study. Neurology. 2010;75:712–7.PubMedCrossRef
80.
Barmherzig R, Lagman-Bartolome AM, Marlowe S, Kohut SA, Gunn G, Olivieri H, et al. Headache hygiene in pediatrics: brushing up on the basics. Pediatr Neurol. 2020;103:3–7.PubMedCrossRef
81.
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.CrossRef
82.
Ng QX, Venkatanarayanan N, Kumar L. A systematic review and meta-analysis of the efficacy of cognitive behavioral therapy for the management of pediatric migraine. Headache. 2017;57(3):349–62.PubMedCrossRef
83.
Eccleston C, Palermo TM, Williams A, et al. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. 2014;CD003968.
84.
Trautmann E, Lackschewitz H, Kroner-Herwig B. Psychological treatment of recurrent headache in children and adolescents: a meta-analysis. Cephalalgia. 2006;26:1411e1426.CrossRef
85.
Powers SW, Kashikar-Zuck SM, Allen JR, LeCates SL, Slater SK, Zafar M, et al. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. JAMA. 2013;310(24):2622–30.PubMedPubMedCentralCrossRef
86.
Stubberud A, Varkey E, McCrory DC, Pedersen SA, Linde M. Biofeedback as prophylaxis for pediatric migraine: a meta-analysis. Pediatrics. 2016;138(2):e20160675.PubMedCrossRef
87.
Sansone E, Raggi A, Grignani E, Leonardi M, D’Amico D, Scaratti C, et al. Mindfulness meditation for chronic migraine in pediatric population: a pilot study. Neurol Sci. 2018;39(Suppl 1):111–3.PubMedCrossRef
88.
Orr SL. The evidence for the role of nutraceuticals in the management of pediatric migraine: a review. Curr Pain Headache Rep. 2018;22(5):37.PubMedCrossRef
89.
Yamanaka G, Kanou K, Takamatsu T, Takeshita M, Morichi S, Suzuki S, et al. Complementary and integrative medicines as prophylactic agents for pediatric migraine: a narrative literature review. J Clin Med. 2021;10(1):138.PubMedCentralCrossRef
90.••
Oskoui M, Pringsheim T, Billinghurst L, et al. Practice guideline update summary: pharmacologic treatment for pediatric migraine prevention: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society [published correction appears in Neurology. 2020;94(1):50]. Neurology. 2019;93(11):500-509. This is a comprehensive guideline providing an updated evidence-based recommendation on pharmacologic treatment for migraine prevention in children and adolescents.
91.
Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, et al. Trial of amitriptyline, topiramate, and placebo for 5 pediatric migraine. N Engl J Med. 2017;376:115–24.PubMedCrossRef
92.
Evers S, Marziniak M, Frese A, Gralow I. Placebo efficacy in childhood and adolescence migraine: 27 an analysis of double-blind and placebo-controlled studies. Cephalalgia. 2009;29:436-444. 28 53.
93.
94.
Winner PK, Blumenfeld AM, Eross EJ, Orejudos AC, Mirjah DL, Adams AM, et al. Long-term safety and tolerability of onabotulinumtoxin A treatment in patients with chronic migraine: results of the COMPEL Study. Drug Saf. 2019;42(8):1013–24.PubMedPubMedCentralCrossRef
95.
Vikelis M, Argyriou AA, Dermitzakis EV, Spingos KC, Makris N, Kararizou E. Sustained onabotulinumtoxin A therapeutic benefits in patients with chronic migraine over 3 years of treatment. J Headache Pain. 2018;19(1):87.PubMedPubMedCentralCrossRef
96.
Young WB, Ivan Lopez J, Rothrock JF, Orejudos A, Manack Adams A, Lipton RB, et al. Effects of onabotulinumtoxin A treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study. J Headache Pain. 2019;20(1):12.PubMedPubMedCentralCrossRef
97.
Dodick DW, Turkel CC, DeGryse RE, et al. Onabotulinumtoxin A for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–36.PubMedCrossRef
98.
Kabbouche M, O’Brien H, Hershey AD. Onabotulinumtoxin A in pediatric chronic daily headache. Current neurology and neuroscience reports. 2012;12(2):114–7.PubMedCrossRef
99.
Ali SS, Bragin I, Rende E, Mejico L, Werner KE. Further evidence that onabotulinum toxin is a viable treatment option for pediatric chronic migraine patients. Cureus. 2019;11(3):e4343.PubMedPubMedCentral
100.
Ahmed K, Oas KH, Mack KJ, Garza I. Experience with botulinum toxin type A in medically intractable pediatric chronic daily headache. Pediatr Neurol. 2010;43(5):316–9.PubMedCrossRef
101.
Chan VW, McCabe EJ, MacGregor DL. Botox treatment for migraine and chronic daily headache in adolescents. The Journal of neuroscience nursing: journal of the American Association of Neuroscience Nurses. 2009;41(5):235–43.CrossRef
102.
Marcelo R, Freund B. The efficacy of botulinum toxin in pediatric chronic migraine: a literature review. J Child Neurol. 2020;35(12):844–51.PubMedCrossRef
103.
Shah S, Calderon MD, Wu W, Grant J, Rinehart J. Onabotulinumtoxin A (BOTOX®) for prophylactic treatment of pediatric migraine: a retrospective longitudinal analysis. J Child Neurol. 2018;33(9):580–6.PubMedCrossRef
104.
Shah S, Calderon M, Crain N, et al. Effectiveness of onabotulinumtoxin A (BOTOX) in pediatric patients experiencing migraines: a randomized, double-blinded, placebo-controlled crossover study in the pediatric pain population. Reg Anesth Pain Med. 2021;46:41–8.PubMedCrossRef
105.
Szperka CL, VanderPluym J, Orr SL, Oakley CB, Qubty W, Patniyot I, et al. Recommendations on the use of anti-CGRP monoclonal antibodies in children and adolescents. Headache. 2018;58(10):1658–69.PubMedPubMedCentralCrossRef
106.
Greene KA, Gentile CP, Szperka CL, Yonker M, Gelfand AA, Grimes B, et al. Calcitonin gene-related peptide monoclonal antibody use for the preventive treatment of refractory headache disorders in adolescents. Pediatr Neurol. 2021;114:62–7.PubMedCrossRef
107.
Börner C, Urban G, Beaulieu LD, Sollmann N, Krieg SM, Straube A, et al. The bottom-up approach: non-invasive peripheral neurostimulation methods to treat migraine: a scoping review from the child neurologist’s perspective. Eur J Paediatr Neurol. 2021;32:16–28.PubMedCrossRef
108.
Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381:2230–41.PubMedCrossRef
109.
Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381:142–9.PubMedCrossRef
110.
Wietecha L, Kuca B, Asafu-Adjei J, et al. Phase 3 studies (SAMURAI, SPARTAN) of lasmiditan compared to placebo for acute treatment of migraine (S50.008). Neurology. 2018;90.
111.
Tsai M, Nery ESM, Kerr L, Khanna R. Komori M. Wilbraham D, Winner P. Pharmacokinetics, safety, and tolerability of lasmiditan in pediatric patients with migraine. Clin Pharmacokinet: Dennehy EB; 2021.
Metadaten
Titel
Approach to Pediatric Intractable Migraine
verfasst von
Mohammed Alqahtani
Rebecca Barmherzig
Ana Marissa Lagman-Bartolome
Publikationsdatum
01.08.2021
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 8/2021
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-021-01128-9

Weitere Artikel der Ausgabe 8/2021

Current Neurology and Neuroscience Reports 8/2021 Zur Ausgabe

Headache (R.B. Halker Singh and J. VanderPluym, Section Editors)

Debunking Myths: Sinus Headache

Behavior (H.S. Kirshner, Section Editor)

The History of Amnesia—a Review

Neurology of Systemic Diseases (J. Biller, Section Editor)

Neurologic Manifestations of the Antiphospholipid Syndrome — an Update

Dementia (K.S. Marder, Section Editor)

Critical Appraisal of Amyloid Lowering Agents in AD

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise